|
US7037922B1
(en)
*
|
2000-03-10 |
2006-05-02 |
Neurogen Corporation |
Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
|
|
JP2002540203A
(ja)
|
1999-03-29 |
2002-11-26 |
ニューロゲン コーポレイション |
Ｎｋ−３および／またはｇａｂａ（ａ）受容体リガンドとしての４−置換キノリン誘導体
|
|
DE60022508T2
(de)
|
1999-06-14 |
2006-06-08 |
Eli Lilly And Co., Indianapolis |
Inhibitoren von serin proteasen
|
|
GEP20053530B
(en)
|
1999-10-19 |
2005-05-25 |
Merck & Co Inc |
Tyrosine Kinase Inhibitors, Pharmaceutical Compositions Containing Them and Use Thereof
|
|
US6794393B1
(en)
|
1999-10-19 |
2004-09-21 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6420382B2
(en)
|
2000-02-25 |
2002-07-16 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6313138B1
(en)
|
2000-02-25 |
2001-11-06 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
US6521618B2
(en)
|
2000-03-28 |
2003-02-18 |
Wyeth |
3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
|
|
AU2002226877B2
(en)
|
2000-10-17 |
2006-01-12 |
Merck & Co., Inc. |
Orally active salts with tyrosine kinase activity
|
|
GB0028964D0
(en)
*
|
2000-11-28 |
2001-01-10 |
Smithkline Beecham Spa |
Novel compounds
|
|
WO2003037252A2
(en)
|
2001-10-30 |
2003-05-08 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
|
EP1541149A1
(en)
*
|
2002-06-26 |
2005-06-15 |
Kyowa Hakko Kogyo Co., Ltd. |
Phosphodiesterase inhibitor
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
DE602004028678D1
(de)
|
2003-01-28 |
2010-09-23 |
Ironwood Pharmaceuticals Inc |
Zusammensetzungen zur Behandlung von Magen-Darm-Störungen
|
|
RU2229475C1
(ru)
*
|
2003-03-06 |
2004-05-27 |
ООО "Исследовательский институт химического разнообразия |
6-сульфамоилхинолин-4-карбоновые кислоты, их производные и комбинаторная библиотека
|
|
TW200804288A
(en)
|
2005-12-12 |
2008-01-16 |
Astrazeneca Ab |
Alkylsulphonamide quinolines
|
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US20090118135A1
(en)
*
|
2007-06-08 |
2009-05-07 |
The Burnham Institute |
Methods and compounds for regulating apoptosis
|
|
EP2810951B1
(en)
|
2008-06-04 |
2017-03-15 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2018129556A1
(en)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
NO2384318T3
(enExample)
|
2008-12-31 |
2018-04-14 |
|
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
MX366293B
(es)
|
2012-08-21 |
2019-07-04 |
Ardelyx Inc |
Compuestos y metodos para inhibir al antipuerto mediado por nhe en el tratamiento de trastornos asociados con la retencion de fluidos o la sobrecarga de sal y trastornos del tracto gastrointestinal.
|
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
|
EP3552630A1
(en)
|
2013-04-12 |
2019-10-16 |
Ardelyx, Inc. |
Nhe3-binding compounds for inhibiting phosphate transport
|
|
CA2909752A1
(en)
|
2013-04-19 |
2014-10-23 |
Astrazeneca Ab |
A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
|
|
CN105764916B
(zh)
|
2013-06-05 |
2021-05-18 |
博士医疗爱尔兰有限公司 |
鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
|
|
WO2016007532A1
(en)
*
|
2014-07-08 |
2016-01-14 |
Dow Agrosciences Llc |
Process for the preparation of 3-hydroxypicolinic acids
|
|
WO2017072629A1
(en)
|
2015-10-29 |
2017-05-04 |
Cadila Healthcare Limited |
Pharmaceutical combination of nk3 receptor antagonist and biguanides
|
|
US11242337B2
(en)
|
2017-01-09 |
2022-02-08 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
|
BR112019013963A2
(pt)
|
2017-01-09 |
2020-04-28 |
Ardelyx Inc |
inibidores de antiporte mediado por nhe
|
|
EP3881843A4
(en)
*
|
2018-11-15 |
2022-08-03 |
Kyushu University, National University Corporation |
PROPHYLACTIC OR THERAPEUTIC AGENT AND MEDICINAL COMPOSITION FOR IL-31-MEDIATED DISEASE
|